There is substantial experimental evidence in both mouse models and in humans documenting the effectiveness of non-steroidal anti-inflammatory drugs, particularly selective COX-2 inhibitors, in reducing both colorectal tumor formation and progression [7], [40]–[42]. This evidence concerns the gene PTGS2 and colorectal neoplasm.